Form 8-K Moderna, Inc. For: Feb 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Warren Buffett transitions to Berkshire’s chairman emeritus
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
Moderna (MRNA) PT Lowered to $185 at Morgan Stanley Following EPS
February 23, 2023 12:39 PM ESTMorgan Stanley analyst Matthew Harrison lowered the price target on Moderna (NASDAQ: MRNA) to $185.00 (from $205.00) while maintaining a Overweight rating following earnings.
The analyst commented, "4Q22 was generally in-line. 2023 COGS of 35-40% was above expectations and the most notable downside driver in our... More
